A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination with Standard Doublet Therapy of Pemetrexed/Carboplatin in Patients with Stage IV (TNM M1a and M1b) Recurrent or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; L-DOS 47 (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions
Sponsors Helix BioPharma

Most Recent Events

14 Jun 2021 According to Helix BioPharma Corp media release, final clinical study report will be completed September 2021
31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
02 Apr 2020 According to a Helix BioPharma media release, the study reports are being compiled and an abstract has been submitted to a conference.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight